Antigens of persistent Chlamydia pneumoniae within coronary atheroma from patients undergoing heart transplantation

Aims In order for Chlamydia pneumoniae to play a causative role in chronic human disease, it would need to persist within infected tissue for extended periods of time. Current theory suggests that C pneumoniae may persist at the site of infection via an alternative replicative form, known as an aberrant body. Methods A panel of C pneumoniae-specific antibodies upregulated by the aberrant body was used to probe tissue specimens from the coronary atheroma from 13 explanted hearts to identify patterns of reactivity in these tissues, as well as to determine the presence and prevalence of C pneumoniae aberrant bodies. Results Six of 13 patients had an ischaemic cardiomyopathy secondary to coronary atherosclerosis, while another six patients had an idiopathic, dilated cardiomyopathy. One additional patient, a young (24 years) woman with cardiomyopathy, had no history of atherosclerotic disease. Eleven patients were positive by immunohistochemistry with at least one antibody. Coronary arteries of the two other patients were negative by immunohistochemistry with all antibodies. One of these patients was the 24-year-old woman with grade I disease and no risk factors for coronary artery disease. Conclusions The protein antigens of persistent C pneumoniae infection found in the atheromatous lesions from patients in this study could potentially be used as markers to detect such infections and some may be virulence factors or immunogens specific to C pneumoniae, thus serving as target molecules for diagnostic use or therapeutic intervention.

[1]  P. Wyrick Chlamydia trachomatis persistence in vitro: an overview. , 2010, The Journal of infectious diseases.

[2]  J. Rupp,et al.  Chlamydia pneumoniae-Induced Memory CD4+ T-Cell Activation in Human Peripheral Blood Correlates with Distinct Antibody Response Patterns , 2010, Clinical and Vaccine Immunology.

[3]  A. Pospischil,et al.  Aberrant chlamydial developmental forms in the gastrointestinal tract of pigs spontaneously and experimentally infected with Chlamydia suis. , 2009, Veterinary microbiology.

[4]  P. Timms,et al.  Chlamydia trachomatis responds to heat shock, penicillin induced persistence, and IFN-gamma persistence by altering levels of the extracytoplasmic stress response protease HtrA , 2008, BMC Microbiology.

[5]  A. Walch,et al.  Cytopathicity of Chlamydia is largely reproduced by expression of a single chlamydial protease , 2008, The Journal of cell biology.

[6]  J. Ramirez,et al.  Evidence for persistent Chlamydia pneumoniae infection of human coronary atheromas. , 2008, Atherosclerosis.

[7]  M. Przybylski,et al.  Immunoproteomic Identification and Serological Responses to Novel Chlamydia pneumoniae Antigens That Are Associated with Persistent C. pneumoniae Infections1 , 2008, The Journal of Immunology.

[8]  Jonathan M. Harris,et al.  The temperature activated HtrA protease from pathogen Chlamydia trachomatis acts as both a chaperone and protease at 37 °C , 2007 .

[9]  Y. Kawana,et al.  CD1d Degradation in Chlamydia trachomatis-infected Epithelial Cells Is the Result of Both Cellular and Chlamydial Proteasomal Activity* , 2007, Journal of Biological Chemistry.

[10]  Ding Chen,et al.  Localization of the hypothetical protein Cpn0585 in the inclusion membrane of Chlamydia pneumoniae-infected cells. , 2007, Microbial pathogenesis.

[11]  J. Ramirez,et al.  Tissue MicroArray (TMA) analysis of normal and persistent Chlamydophila pneumoniae infection , 2006, BMC infectious diseases.

[12]  P. Timms,et al.  Protein Expression Profiles of Chlamydia pneumoniae in Models of Persistence versus Those of Heat Shock Stress Response , 2006, Infection and Immunity.

[13]  Stefanie Goellner,et al.  Optimized DNA microarray assay allows detection and genotyping of single PCR-amplifiable target copies. , 2006, Molecular and cellular probes.

[14]  G. Zhong,et al.  Human Antibody Responses to a Chlamydia-Secreted Protease Factor , 2004, Infection and Immunity.

[15]  P. Timms,et al.  Chlamydial Persistence: beyond the Biphasic Paradigm , 2004, Infection and Immunity.

[16]  T. Meyer,et al.  Expression and translocation of chlamydial protease during acute and persistent infection of the epithelial HEp‐2 cells with Chlamydophila (Chlamydia) pneumoniae , 2003, Cellular microbiology.

[17]  Peter Libby,et al.  Chlamydia pneumoniae as an emerging risk factor in cardiovascular disease. , 2002, JAMA.

[18]  W. H. Pierce,et al.  Proteomic Analysis of Differentially Expressed Chlamydia pneumoniae Genes during Persistent Infection of HEp-2 Cells , 2002, Infection and Immunity.

[19]  P. Roholl,et al.  Chlamydia pneumoniae in vitro and in vivo: a critical evaluation of in situ detection methods , 2000, Journal of clinical pathology.

[20]  P. Roholl,et al.  Chlamydia pneumoniae antigens, rather than viable bacteria, persist in atherosclerotic lesions , 2000, Journal of clinical pathology.

[21]  L. Jackson,et al.  Chlamydia pneumoniae (TWAR) , 1995, Clinical microbiology reviews.

[22]  Grayston Jt Infections caused by Chlamydia pneumoniae strain TWAR. , 1992 .

[23]  J. Altman,et al.  A new Chlamydia psittaci strain, TWAR, isolated in acute respiratory tract infections. , 1986, The New England journal of medicine.

[24]  Jonathan M. Harris,et al.  The temperature activated HtrA protease from pathogen Chlamydia trachomatis acts as both a chaperone and protease at 37 degrees C. , 2007, FEBS letters.

[25]  Philip Smith,et al.  Persistent infection with Chlamydia pneumoniae following acute respiratory illness. , 1992, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[26]  J. Grayston Infections caused by Chlamydia pneumoniae strain TWAR. , 1992, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.